Oncology Today with Dr Neil Love

Oncology Today with Dr Neil Love is a clinical oncology program organized around decisions, not general interest storytelling. It treats each episode as a working session. A paper, conference abstract, patient case, or community-oncologist question establishes the practical problem. From there, the conversation narrows into biomarker testing, treatment choice, sequencing, response assessment, and management of adverse effects. Recent installments return often to ctDNA and MRD, especially in non-small cell lung cancer, breast cancer, and localized colorectal cancer. The show is especially interested in what molecular evidence can and cannot justify before a scan changes. That makes the discussions useful, but also deliberately cautious. Positive prognostic information is not presented as automatic clinical action. In metastatic breast cancer episodes, tissue and liquid biopsy, ESR1 testing, HER2 status, endocrine therapy, maintenance therapy, and oral CERDs become tools for sorting real choices. In bladder cancer, case reviews move through treatment combinations, HER2 findings, BCG, PD-L1 agents, and toxicity lessons borrowed from other tumor settings. Desmoid tumor coverage emphasizes restraint as much as treatment, including active surveillance, symptom burden, anatomical risk, and finite courses of therapy. Multiple myeloma coverage turns quickly from meeting excitement to the mechanics and uncertainties of BCMA-targeted therapy and in vivo CAR T-cell approaches. The rhythm is brisk and procedural. It does not pause for atmosphere. Its value comes from hearing experienced clinicians translate research signals into the kinds of hedged, patient-specific judgments that shape oncology practice. The show suits listeners who are already fluent in the field and want a structured update that respects both evidence and uncertainty.